Wang et al. identified SHP2 as a central node in MPNST pathogenesis and the combination of an SHP2 inhibitor and MEK inhibitor looked promising in vivo, in MPNST models [88]. Here, PTPN11 is linked to malignant peripheral nerve sheath tumor.